BioNTech (BNTX) Q3 2024 earnings summary

Executive summary

• Achieved strong Q3 2024 performance with global rollout of updated COVID-19 vaccines and significant advancements in the oncology pipeline, including new Phase 2 trials and positive data for BNT327 and mRNA cancer vaccines.

• Presented key clinical updates at ESMO Congress, initiated new trials in bladder, lung, and breast cancer, and provided regulatory submission plans for 2025.

• Showcased AI capabilities through inaugural AI Day and integration of InstaDeep, highlighting commitment to AI-driven innovation and new partnerships.

• Maintained robust liquidity with €17.8 billion in cash and security investments at quarter-end.

Financial highlights

• Q3 2024 revenues reached €1,245 million, up from €895 million in Q3 2023; nine-month revenues declined to €1,561.1 million from €2,340.0 million year-over-year.

• Net income for Q3 2024 was €198.1 million, up from €160.6 million in Q3 2023; nine-month net loss of €924.8 million compared to a profit of €472.4 million prior year.

• Diluted EPS for Q3 2024 was €0.81, up from €0.66; nine-month loss per share was €3.83 versus prior year EPS of €1.94.

• Cash and equivalents plus security investments totaled €17.8 billion as of September 30, 2024.

• Operating profit for Q3 2024 was €10.5 million, down from €73.1 million in Q3 2023.

Outlook and guidance

• Full-year 2024 revenues expected at the low end of the €2.5–€3.1 billion guidance range due to lower demand and pricing in some markets.

• Anticipates a net loss for FY 2024 as investments in pipeline and technology continue.

• SG&A expense guidance lowered by €100 million to €600–€700 million; CapEx guidance reduced to €300–€400 million.

• R&D expense guidance maintained at €2.4–€2.6 billion; guidance excludes future M&A or legal settlements.